CytoMed Therapeutics GDTC
NASDAQ GDTC
$0.91 +0.04 (+4.42%)
As of: Oct 21, 2026 · 3:59 PM EDT

CytoMed Therapeutics (GDTC) Total Debt (2021 - 2026)

Updated

CytoMed Therapeutics (GDTC) reported Total Debt of $741,445 for Q2 2026, compared with $38,264 a year earlier.

Analysis

CytoMed Therapeutics (GDTC) Total Debt (2021 - 2026) Analysis & Trends

At the end of FY2025, CytoMed Therapeutics posted Total Debt of $313,433, up 380.7% from FY2024.

  • Total Debt has a four-year compound annual growth rate of -43.1% (FY2021 to FY2025).
  • By year, Total Debt came in at $65,208 in FY2024 (+9.3%), $59,641 in FY2023 (-98.4%), $3.77 million in FY2022 (+26.4%) and $2.98 million in FY2021.
  • The Q2 2026 figure ranks as the highest quarterly Total Debt since Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 54.91 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 49.04 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 70.82 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 53.91 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 9.59 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 32.35 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 57.30 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 26.25 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 63.19 Bn
10 CytoMed Therapeutics 9.44 Mn -158,924.18 - 41,845.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 41,845.00
Dec 31, 2025 318,952.40
Jun 30, 2025 410,766.00
Dec 31, 2024 317,788.24
Jun 30, 2024 425,720.00
Dec 31, 2023 334,670.40
Jun 30, 2023 462,071.00
Dec 31, 2022 4.00 Mn
Dec 31, 2021 2.99 Mn
API Access

CytoMed Therapeutics Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=GDTC&period=max&api_key=YOUR_API_KEY